BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioMarin excels in Q4 with record revenues and gene therapy launch

BioMarin Pharmaceutical reported strong financial results in Q4 2022, achieving revenue growth, profitability, and successful introduction of the ROCTAVIAN gene therapy for hemophilia A.
The company's performance highlights its R&D capabilities, market positioning, and strategic readiness for upcoming product launches, positioning BioMarin for continued growth and innovation.
While facing challenges in reimbursement processes and regulatory requirements, BioMarin has opportunities to drive revenue expansion, market penetration, and address unmet medical needs through its innovative pipeline.

BioMarin reports strong Q1 earnings, eyes blockbuster status for ROCTAVIAN

BioMarin Pharmaceuticals had a robust Q1 2023, focusing on revenue growth, profitability, and commercial readiness for key drug launches. While facing challenges in Germany, the company is optimistic about the potential of ROCTAVIAN and VOXZOGO in driving future growth.

BioMarin excels in Q2 with record revenues and treatment milestones

BioMarin's strong Q2 performance, driven by record revenues and product demand, positions the company for growth.
Challenges like supply issues and site readiness are being addressed, while opportunities in new programs and markets are promising.
Overall, BioMarin's focus on compliance, expansion, and pipeline development sets a positive trajectory for future success.

BioMarin reports strong Q3 revenue growth, eyes Roctavian expansion

BioMarin's Q3 performance showed revenue growth driven by Voxzogo, with strong expectations for 2024 revenue.
New CEO Alexander Hardy is set to continue the core strategy, focusing on Roctavian's global launch and Voxzogo's growth potential.
Challenges include delays in Roctavian's takeoff and supply constraints for Voxzogo, but efforts are underway to address these issues.
Opportunities lie in Roctavian's revenue contribution, Voxzogo's U.S. growth potential, and leveraging CNP for stature improvements.

BioMarin posts robust Q4 earnings, eyes expansion in gene therapy

BioMarin Pharmaceutical delivered strong financial results in Q4 2023, driven by revenue growth and increased earnings per share. The company's focus on high-impact medicines and gene therapy expertise positions it well for future growth.
While facing challenges related to analyst inquiries and market adoption of key products like Roctavian and Voxzogo, BioMarin remains committed to innovation and optimizing its business model.
Opportunities lie in expanding product reach, maximizing shareholder value through strategic capital allocation, and driving innovation in transformative programs. BioMarin's long-term strategy and growth potential remain promising.

BioMarin reports record revenue, focuses on key assets for growth

BioMarin Pharmaceutical's Q1 2024 performance reflects strong revenue growth and financial stability, driven by key product demand.
While facing challenges such as revenue impact and supply constraints, the company's strategic focus on key assets and cost reduction initiatives bode well for future growth.
Opportunities lie in expanding Voxzogo's market reach, optimizing manufacturing capabilities, and maintaining a competitive edge in innovative treatments.

BioMarin Pharmaceuticals reports record revenue and profitability outlook for 2024

BioMarin Pharmaceuticals delivered strong financial performance in Q2 2024, driven by robust revenue growth and strategic decisions. The company's focus on profitability, expansion of key treatments, and progress in R&D highlight a promising outlook. Addressing analyst inquiries and leveraging upcoming events can further enhance investor confidence and market positioning.

BioMarin reports record Q3 revenues, eyes long-term growth targets

BioMarin Pharmaceuticals showcased robust financial performance and raised full-year guidance.
The company remains optimistic about its long-term growth prospects and is committed to defending its IP.
Strategic focus on expanding global reach and driving growth in enzyme therapies portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.36 per share a year ago.

BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates

Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y) VOXZOGO® Net Revenues of $146 Million in Q4'23 (+118% Q/Q) and $470 Million for FY'23 (+178% Y/Y) BioMarin's 2024 Financial Outlook Reflects Anticipated Double-digit Total Revenue Growth, Significant Non-GAAP Operating Margin Expansion, and Non-GAAP Earnings Per Share Growing Faster than Revenues Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024

American Homes 4 Rent

Booking Hlds

Floor & Decor Holdings

Pembina Pipeline

We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.

5 Stocks Likely to Gain on Q4 Earnings Today After Market Close

Bausch Health Companies Inc

Intra-Cellular Therapies

Moderna

Intellia Therapeutics

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for BioMarin (BMRN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Seeking Clues to BioMarin (BMRN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

Amarin Corporation Plc

Beam Therapeutics

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Agios Pharmaceuticals

Alkermes

Arrowhead Pharmaceuticals

Biogen

Bristol-Myers

Gilead Sciences

Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.

7 Biotech Stocks Fighting America's Deadliest Diseases

SAN RAFAEL, Calif. , Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET

New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostatic Benefit for Adults with Severe Hemophilia A SAN RAFAEL, Calif. , Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.

Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?

Innoviva

IQVIA Hlds

The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it for their growth and development. Without the work of these companies, we would still be using very old and ineffective medicines.

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names

SAN RAFAEL, Calif. , Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P.

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA

Amgen

AstraZeneca

Blueprint Medicines

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

NEW YORK, Dec 20 (Reuters) - BioMarin (BMRN.O) reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its board and form a committee to review operations.

BioMarin settles with Elliott, adds 3 independent directors

Board Approves Appointment of Three New Independent Directors Company Establishes Strategic and Operating Review Committee of the Board BioMarin Enters into Cooperation and Information Sharing Agreements with Elliott SAN RAFAEL, Calif. , Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?

ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany SAN RAFAEL, Calif. , Nov. 28, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for ROCTAVIAN ® (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A.

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany

Exelixis

Halozyme Therapeutics

In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector's most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow's Cures

Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly and indirectly help our well-being.

3 Promising Biotech Stocks Flying Under the Radar

Among the large-cap stocks making big moves in today's market is drug maker BioMarin Pharmaceuticals (NASDAQ: BMRN ). Shares of BMRN stock surged more than 12% in early afternoon trading today on news that Elliott Investment Management has built a stake in the company and has been working behind the scenes with management for “months,” signaling strong interest from the activist investor in this name.

BMRN Stock Jumps 12% as Activist Elliott Targets BioMarin Pharmaceuticals

Activist investor Elliott has reportedly built a $1 billion stake in BioMarin Pharmaceutical, Reuters reported Tuesday as BMRN stock rocketed.

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake

Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter.

News for BioMarin Pharmaceutical Stock (BMRN)